Unichem Laboratories Ltd

Unichem Labs. Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Unichem Laboratories Ltd

₹ 591 2.67%
24 Apr - close price
unichemlabs.com BSE: 506690 NSE : UNICHEMLAB
About

Unichem Laboratories Ltd is involved in pharmaceuticals
in Generics, APIs and Contract Manufacturing (CMO) areas.[1]

Key Points

Therapeutic Areas
The company manufactures a wide range of APIs and pharmaceutical formulations as branded and simple generics. Its products cater to diverse range of therapeutic areas, such as cardiology, gastroenterology, diabetology, psychiatry, neurology and others. [1]

Website BSE NSE
  • Market Cap ₹ 4,164 Cr.
  • Current Price ₹ 591
  • High / Low ₹ 607 / 365
  • Stock P/E
  • Book Value ₹ 342
  • Dividend Yield 0.00 %
  • ROCE -4.58 %
  • ROE -7.05 %
  • Face Value ₹ 2.00
Edit ratios

Pros

  • Company has been maintaining a healthy dividend payout of 51.1%

Cons

  • Company has low interest coverage ratio.
  • The company has delivered a poor sales growth of 10.5% over past five years.
  • Company has a low return on equity of -1.57% over last 3 years.
  • Earnings include an other income of Rs.65.0 Cr.
  • Company has high debtors of 160 days.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
326 274 298 291 311 370 310 329 302 402 423 416 434
296 255 300 284 313 302 311 347 345 386 395 407 396
Operating Profit 30 19 -2 6 -1 68 -1 -18 -43 16 28 9 38
OPM % 9% 7% -1% 2% -0% 18% -0% -6% -14% 4% 7% 2% 9%
16 8 16 3 15 14 8 4 16 -28 9 6 79
Interest 1 2 1 2 1 2 3 5 4 6 6 7 6
Depreciation 21 22 22 22 23 23 25 28 31 30 29 29 28
Profit before tax 23 3 -9 -16 -11 58 -21 -47 -61 -47 2 -22 84
Tax % -0% 114% -27% 17% -24% -23% -13% -50% -4% 6% 132% -12% -0%
24 -0 -11 -13 -14 71 -23 -71 -64 -44 -1 -24 84
EPS in Rs 3.35 -0.06 -1.63 -1.82 -2.00 10.15 -3.32 -10.04 -9.08 -6.29 -0.10 -3.48 11.93
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 TTM
875 1,081 1,133 1,202 1,333 698 815 1,180 1,104 1,235 1,270 1,343 1,675
757 906 956 1,100 1,169 738 942 1,254 1,153 1,144 1,198 1,389 1,584
Operating Profit 118 174 178 101 164 -41 -128 -74 -49 91 72 -46 91
OPM % 14% 16% 16% 8% 12% -6% -16% -6% -4% 7% 6% -3% 5%
10 13 83 20 15 184 2,735 91 91 50 47 -0 65
Interest 4 3 3 3 3 3 8 8 8 5 6 17 24
Depreciation 30 38 46 41 39 44 51 67 82 84 91 113 116
Profit before tax 94 146 212 77 137 97 2,548 -58 -48 51 22 -176 17
Tax % 24% 22% 20% 3% 21% -12% 0% 59% -25% 33% -50% -15%
71 113 169 75 108 109 2,545 -24 -60 34 33 -202 15
EPS in Rs 7.89 12.52 18.68 8.31 11.90 11.96 361.82 -3.38 -8.55 4.87 4.70 -28.72 2.06
Dividend Payout % 38% 36% 43% 24% 17% 25% 1% -118% -47% 82% 85% -14%
Compounded Sales Growth
10 Years: 2%
5 Years: 11%
3 Years: 7%
TTM: 28%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: %
TTM: 76%
Stock Price CAGR
10 Years: 11%
5 Years: 25%
3 Years: 19%
1 Year: 53%
Return on Equity
10 Years: 15%
5 Years: -2%
3 Years: -2%
Last Year: -7%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Sep 2023
Equity Capital 18 18 18 18 18 18 14 14 14 14 14 14 14
Reserves 643 709 798 849 936 1,045 2,666 2,606 2,517 2,543 2,604 2,421 2,394
46 27 26 22 36 98 151 200 206 119 349 314 290
280 318 302 264 283 359 359 323 407 436 351 444 372
Total Liabilities 987 1,073 1,145 1,153 1,274 1,521 3,190 3,142 3,145 3,112 3,319 3,193 3,070
408 448 419 416 403 491 578 810 870 884 990 1,257 1,227
CWIP 113 132 91 123 237 250 238 92 330 568 494 147 122
Investments 15 39 11 41 14 14 901 926 550 392 264 2 2
451 454 623 574 620 766 1,473 1,313 1,395 1,269 1,571 1,787 1,720
Total Assets 987 1,073 1,145 1,153 1,274 1,521 3,190 3,142 3,145 3,112 3,319 3,193 3,070

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
124 171 87 78 112 68 -112 -328 20 33 -260 -85
-102 -118 36 -52 -85 -132 1,648 -286 -36 -66 100 241
-14 -51 -95 -51 -33 59 -881 -2 -62 -121 191 -81
Net Cash Flow 8 1 28 -25 -7 -4 655 -616 -78 -154 32 75

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Debtor Days 76 70 63 58 60 165 124 135 129 74 142 160
Inventory Days 183 132 192 171 184 397 278 278 374 518 527 414
Days Payable 162 145 142 114 131 297 230 182 236 202 161 193
Cash Conversion Cycle 97 57 113 116 113 265 172 231 267 390 508 382
Working Capital Days 81 59 95 89 94 225 200 227 217 194 277 273
ROCE % 14% 20% 19% 9% 15% 9% 128% -2% -2% 2% 1% -5%

Shareholding Pattern

Numbers in percentages

Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024
50.93% 50.93% 50.93% 50.93% 50.93% 50.94% 50.94% 50.94% 50.94% 70.21% 70.22% 70.22%
1.54% 1.53% 1.45% 1.47% 1.50% 1.71% 1.56% 1.70% 1.62% 0.83% 0.84% 0.90%
9.09% 9.09% 9.30% 9.59% 9.53% 8.70% 8.21% 8.15% 9.65% 10.00% 10.46% 11.26%
38.43% 38.44% 38.32% 38.01% 38.04% 38.67% 39.31% 39.21% 37.80% 18.95% 18.47% 17.63%
No. of Shareholders 34,25833,89235,31333,55732,66629,57330,61829,41826,64221,58420,87721,171

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls